Prosecution Insights
Last updated: July 17, 2026
Application No. 18/320,315

SYSTEM AND METHOD FOR CELL AND TISSUE PREPARATION

Non-Final OA §102§103§112
Filed
May 19, 2023
Priority
Jun 17, 2019 — provisional 62/862,379 +1 more
Examiner
KRCHA, MATTHEW D
Art Unit
Tech Center
Assignee
DEKA Products Limited Partnership
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
366 granted / 560 resolved
+5.4% vs TC avg
Strong +35% interview lift
Without
With
+35.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
63 currently pending
Career history
631
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
85.5%
+45.5% vs TC avg
§102
5.3%
-34.7% vs TC avg
§112
4.0%
-36.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 560 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 recites the limitation "the pre-selected event" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites a first and second pre-selected even and claim 3 is unclear which pre-selected event claim 3 is referring to. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 4, 5, 12 and 13 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by United States Application Publication No. 2017/0175063, hereinafter Smith. Regarding claim 1, Smith teaches a method for the automatic manufacture of tissue (figure 17) comprising: receiving cells in a fluid suspension in at least one vial (paragraph [0199], item 322); pumping the cells in the fluid suspension from the at least one vial to at least one first bioreactor (paragraph [0199], item 300); creating a first pre-selected environment to promote expansion of the cells in the at least one first bioreactor (paragraph [0203]); pumping the expanded cells from the at least one first bioreactor to a concentrator when the expanded cells have reached a pre-selected density (paragraph [0203]); concentrating the expanded cells (paragraphs [0203]-[0204]); pumping the concentrated cells into the at least one first bioreactor when a pre-selected event has occurred (paragraph [0203]); resuspending the concentrated cells (paragraph [0203]); pumping the cells from the at least one first bioreactor to at least one second bioreactor when the concentrated cells are resuspended (paragraph [0204]); and creating a second pre-selected environment promoting maturation of the concentrated cells into the tissue in the at least one second bioreactor (paragraph [0204]). Regarding claim 4, Smith teaches wherein the first pre-selected environment comprises a first growth media, the first growth media being continuously automatically adjusted based on monitoring sensor data of critical process parameters to maintain first pre-selected levels of growth media characteristics (paragraph [0202]). Regarding claim 5, Smith teaches wherein the second pre-selected environment comprises second growth media, the second growth media being continuously automatically adjusted based on monitoring of sensor data of critical process parameters to maintain second pre- selected levels of growth media characteristics (paragraph [0204]). Regarding claim 12, Smith teaches further comprising: agitating the cells to encourage attachment of the cells to a surface (paragraph [0182]); adjusting a temperature of the at least one first bioreactor based on a pre-selected desired temperature (paragraph [0177]); adjusting levels of a gas in media surrounding the cells, the levels of gas based on pre- selected desired values of characteristics of the media (paragraph [0177]); sensing values of the characteristics of the media (paragraph [0180]); and moving the media to and from the at least one first bioreactor (paragraph [0184]). Regarding claim 13, Smith teaches wherein the characteristics comprise dissolved oxygen and pH (paragraphs [0177] and [0180]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 2 is/are rejected under 35 U.S.C. 103 as being unpatentable over Smith in view of United States Application Publication No. 2016/0252537, hereinafter Murali. Regarding claim 2, Smith teaches all limitations of claim 10; however, Smith teaches the concentrating the expanded cells comprise a filtration concentrator (paragraph [0203]) and not a centrifugation device. Murali teaches the use of filtration or centrifugation to concentrate cells (Murali, paragraph [0042]). Examiner further finds that the prior art contained a device/method/product (i.e., a centrifugation device) which differed from the claimed device by the substitution of component(s) (i.e., a filtration device) with other component(s) (i.e., a centrifugation device), and the substituted components and their functions were known in the art as above set forth. An ordinarily skilled artisan at the time of invention could have substituted one known element with another (i.e., a filtration device with a centrifugation device), and the results of the substitution (i.e., concentrating the cells) would have been predictable. Therefore, pursuant to MPEP $2143 (I), Examiner concludes that it would have been obvious to an ordinarily skilled artisan at the time of invention to substitute the filtration device of reference Smith with the centrifugation device of reference Murali, since the result would have been predictable. Claim(s) 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Smith in view of United States Application Publication No. 2011/0020856, hereinafter Poo. Regarding claim 3, Smith teaches all limitations of claim 1; however, Smith fails to teach the pre-selected event comprises a detection of a desired concentration. Poo teaches a method in which the controller controls operation of the pumps to obtain a desired final concentration of the substance flowing into the sample container (Poo, paragraph [0031]). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have had the pre-selected event comprises a detection of a desired concentration because it would allow for the recovery of the desired final concentration of the substance (Poo, paragraph [0031]). Claim(s) 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Smith in view of United States Application Publication No. 2003/0086830, hereinafter Haywood. Regarding claim 6, Smith teaches all limitations of claim 1; however, Smith fails to teach the step of receiving cells further comprising: receiving frozen cells in at least one vial; and thawing the frozen cells to produce cells in a fluid suspension. Haywood teaches that samples are frozen to obtain high quality test results (Haywood, paragraph [0009]). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have received frozen cells and then thaw the frozen cells to produce a fluid suspension because when the samples are frozen at the start, they provide a high-quality test result (Haywood, paragraph [0009]). Allowable Subject Matter Claims 7-11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art of record is Smith which teaches an expansion subsystem with a vial and bioreactor, a concentration subsystem and a maturation subsystem. However, the prior art does not disclose, teach or suggest the claimed combination of the insulated container with a lid and vial holder, removing the insulated container lid using a first gripper; determining a location of the at least one vial within the vial holder; positioning a second gripper at the location of the at least one vial; removing the at least one vial from the insulated container using the second gripper; placing the removed at least one vial into a cell thawing device using the second gripper; determining when the frozen cells are thawed; removing the at least one vial of thawed cells using the second gripper; transferring the at least one vial of thawed cells to a third gripper; and moving the at least one vial of thawed cells to a first pre-selected location. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW D KRCHA whose telephone number is (571)270-0386. The examiner can normally be reached M-Th 7am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maris Kessel can be reached at (571)270-7698. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW D KRCHA/ Primary Examiner, Art Unit 1796
Read full office action

Prosecution Timeline

May 19, 2023
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12681002
HYDROCARBON CONTAMINANT DETECTION USING POLYMER FILM
3y 2m to grant Granted Jul 14, 2026
Patent 12667838
Microfluidic Flow Channel Structure and Microfluidic Chip
3y 5m to grant Granted Jun 30, 2026
Patent 12656333
CLINICAL DECISION SUPPORT SYSTEM
3y 5m to grant Granted Jun 16, 2026
Patent 12644159
DEVICE AND METHODS FOR DETECTING FUNGAL PATHOGENICITY IN POSTHARVEST PRODUCE
3y 11m to grant Granted Jun 02, 2026
Patent 12638399
METHOD FOR DETERMINING TOTAL ALDEHYDES IN ONE OR MORE OF CRUDE 2,5-FURANDICARBOXYLIC ACID (FDCA), CRUDE TEREPHTHALIC ACID (TPA) AND ESTERS OF THESE
3y 5m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+35.3%)
3y 3m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 560 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month